Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a BMI ≤ 40.~* Subject has all of the following:~  1. Established diagnosis of diabetes (Type I or II) with painful diabetic peripheral neuropathy and glycosylated hemoglobin (HgbA1c) ≤ 9.5% at Screening or Randomization.~ 2. Stable diabetic drug regimen for at least 3 months prior to Screening.~ 3. At least a 1 year history of PDPN.~ 4. Diagnosis of PDPN to be confirmed by a score of ≥ 3 on the Michigan Neuropathy Screening Instrument (MNSI) at Screening.~* Subject has pain intensity score(s) ≥ 4 or ≤ 9 on an 11-point numeric pain rating scale (NPRS) at Screening Visit and prior to Randomization.~* Subject agrees to complete pain diaries and is complaint with the daily pain recording prior to Randomization as defined by the completion of a minimum of 5 of 7 daily pain ratings, 3 of which are required in the last 4 days.~* Subject's anti-diabetic regimen is anticipated to be stable throughout the study.~* Subject must be willing to washout of all medications currently being taken for his/her PDPN (chronic and occasional/as needed) and remain off of those pain medications while participating in the study.~Exclusion Criteria:~* Subject has received prior treatment with pregabalin for PDPN and was considered unresponsive or intolerant.~* Subject has tried and failed 3 or more drugs to treat PDPN within the past 3 years. Drugs must have been administered at therapeutic doses and have been administered for an adequate period of time.~* Subject has a known hypersensitivity to ASP3662, pregabalin, gabapentin or acetaminophen, or their formulation components.~* Subject has significant pain (moderate or above) due to causes other than PDPN.~* Subject has a history of painful peripheral neuropathy due to a cause other than diabetes.~* Subject has any lower extremity amputation~* Subject has a current or previous foot ulcer within the past 3 months as described by medical history and/or medical examination.~* Subject has an active malignancy or a history of malignancy (except for treated non-melanoma skin cancer) within 5 years.~* Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine at Screening.~* Subject has creatinine clearance \< 60 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation) at Screening.~* Subject tests positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody at Screening or has a known history of a positive test for human immunodeficiency virus (HIV) infection.~* Subject has a positive drug screen for alcohol or drugs of abuse at Screening and/or Randomization. Subjects who are on low doses of benzodiazepines for sleep with a legitimate prescription will be allowed into the study. In addition, subjects with a positive drug screen at Randomization will be excluded.~* Subject is currently using protocol specified non-permitted medications including OTC products and is unable or does not choose to discontinue them.~* Subject has planned an elective surgery during planned study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ASP3662 (Type: EXPERIMENTAL): ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
- pregabalin (Type: ACTIVE_COMPARATOR): pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
- Placebo (Type: PLACEBO_COMPARATOR): ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).